Literature DB >> 12870105

Evaluating the dizzy patient: bedside examination and laboratory assessment of the vestibular system.

Scott D Z Eggers1, David S Zee.   

Abstract

Dizziness and imbalance are common presenting complaints to the neurologist. The lack of a systematic approach to the examination and laboratory evaluation of the vestibular system often leads to incorrect diagnoses and suboptimal care. With a basic understanding of vestibular physiology and proper examination techniques, a correct diagnosis can generally be made at the bedside. We review the principles of the neuro-otological examination, including assessment for static vestibular imbalance, dynamic vestibular function, provocative maneuvers, ocular motor examination, and vestibulospinal testing. The use of additional vestibular laboratory testing and neuroimaging is then considered to further localize and quantify abnormalities.

Entities:  

Mesh:

Year:  2003        PMID: 12870105     DOI: 10.1055/s-2003-40751

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  4 in total

1.  Nystagmus assessments documented by emergency physicians in acute dizziness presentations: a target for decision support?

Authors:  Kevin A Kerber; Lewis B Morgenstern; William J Meurer; Thomas McLaughlin; Pamela A Hall; Jane Forman; A Mark Fendrick; David E Newman-Toker
Journal:  Acad Emerg Med       Date:  2011-06       Impact factor: 3.451

2.  Glucocorticoids improve acute dizziness symptoms following acute unilateral vestibulopathy.

Authors:  Angel Batuecas-Caletrío; Raquel Yañez-Gonzalez; Carmen Sanchez-Blanco; Pedro Blanco Pérez; Enrique González-Sanchez; Luis Alberto Guardado Sanchez; Diego Kaski
Journal:  J Neurol       Date:  2015-10-12       Impact factor: 4.849

3.  Clinical evaluation of posterior canal benign paroxysmal positional vertigo.

Authors:  Titus S Ibekwe; C Rogers
Journal:  Niger Med J       Date:  2012-04

4.  Current Treatment of Nystagmus.

Authors:  Janet C Rucker
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.